219 related articles for article (PubMed ID: 35835549)
1. Genetic Mapping of APP and Amyloid-β Biology Modulation by Trisomy 21.
Mumford P; Tosh J; Anderle S; Gkanatsiou Wikberg E; Lau G; Noy S; Cleverley K; Saito T; Saido TC; Yu E; Brinkmalm G; Portelius E; Blennow K; Zetterberg H; Tybulewicz V; Fisher EMC; Wiseman FK
J Neurosci; 2022 Aug; 42(33):6453-6468. PubMed ID: 35835549
[TBL] [Abstract][Full Text] [Related]
2. Genetic dissection of down syndrome-associated alterations in APP/amyloid-β biology using mouse models.
Tosh JL; Rhymes ER; Mumford P; Whittaker HT; Pulford LJ; Noy SJ; Cleverley K; ; Walker MC; Tybulewicz VLJ; Wykes RC; Fisher EMC; Wiseman FK
Sci Rep; 2021 Mar; 11(1):5736. PubMed ID: 33707583
[TBL] [Abstract][Full Text] [Related]
3. Targeting increased levels of APP in Down syndrome: Posiphen-mediated reductions in APP and its products reverse endosomal phenotypes in the Ts65Dn mouse model.
Chen XQ; Salehi A; Pearn ML; Overk C; Nguyen PD; Kleschevnikov AM; Maccecchini M; Mobley WC
Alzheimers Dement; 2021 Feb; 17(2):271-292. PubMed ID: 32975365
[TBL] [Abstract][Full Text] [Related]
4. Trisomy of human chromosome 21 enhances amyloid-β deposition independently of an extra copy of APP.
Wiseman FK; Pulford LJ; Barkus C; Liao F; Portelius E; Webb R; Chávez-Gutiérrez L; Cleverley K; Noy S; Sheppard O; Collins T; Powell C; Sarell CJ; Rickman M; Choong X; Tosh JL; Siganporia C; Whittaker HT; Stewart F; Szaruga M; ; Murphy MP; Blennow K; de Strooper B; Zetterberg H; Bannerman D; Holtzman DM; Tybulewicz VLJ; Fisher EMC;
Brain; 2018 Aug; 141(8):2457-2474. PubMed ID: 29945247
[TBL] [Abstract][Full Text] [Related]
5. Normalizing the gene dosage of Dyrk1A in a mouse model of Down syndrome rescues several Alzheimer's disease phenotypes.
García-Cerro S; Rueda N; Vidal V; Lantigua S; Martínez-Cué C
Neurobiol Dis; 2017 Oct; 106():76-88. PubMed ID: 28647555
[TBL] [Abstract][Full Text] [Related]
6. [Elucidating Pathogenic Mechanisms of Early-onset Alzheimer's Disease in Down Syndrome Patients].
Asai M; Kawakubo T; Mori R; Iwata N
Yakugaku Zasshi; 2017; 137(7):801-805. PubMed ID: 28674290
[TBL] [Abstract][Full Text] [Related]
7. Alzheimer's disease amyloid-β pathology in the lens of the eye.
Moncaster JA; Moir RD; Burton MA; Chadwick O; Minaeva O; Alvarez VE; Ericsson M; Clark JI; McKee AC; Tanzi RE; Goldstein LE
Exp Eye Res; 2022 Aug; 221():108974. PubMed ID: 35202705
[TBL] [Abstract][Full Text] [Related]
8. Alzheimer's disease amyloid-beta links lens and brain pathology in Down syndrome.
Moncaster JA; Pineda R; Moir RD; Lu S; Burton MA; Ghosh JG; Ericsson M; Soscia SJ; Mocofanescu A; Folkerth RD; Robb RM; Kuszak JR; Clark JI; Tanzi RE; Hunter DG; Goldstein LE
PLoS One; 2010 May; 5(5):e10659. PubMed ID: 20502642
[TBL] [Abstract][Full Text] [Related]
9. Common genetic signatures of Alzheimer's disease in Down Syndrome.
Sharma A; Chunduri A; Gopu A; Shatrowsky C; Crusio WE; Delprato A
F1000Res; 2020; 9():1299. PubMed ID: 33633844
[No Abstract] [Full Text] [Related]
10. ABCA7 Deficiency Accelerates Amyloid-β Generation and Alzheimer's Neuronal Pathology.
Sakae N; Liu CC; Shinohara M; Frisch-Daiello J; Ma L; Yamazaki Y; Tachibana M; Younkin L; Kurti A; Carrasquillo MM; Zou F; Sevlever D; Bisceglio G; Gan M; Fol R; Knight P; Wang M; Han X; Fryer JD; Fitzgerald ML; Ohyagi Y; Younkin SG; Bu G; Kanekiyo T
J Neurosci; 2016 Mar; 36(13):3848-59. PubMed ID: 27030769
[TBL] [Abstract][Full Text] [Related]
11. Impact of increased APP gene dose in Down syndrome and the Dp16 mouse model.
Sawa M; Overk C; Becker A; Derse D; Albay R; Weldy K; Salehi A; Beach TG; Doran E; Head E; Yu YE; Mobley WC
Alzheimers Dement; 2022 Jun; 18(6):1203-1234. PubMed ID: 34757693
[TBL] [Abstract][Full Text] [Related]
12. BACE2, as a novel APP theta-secretase, is not responsible for the pathogenesis of Alzheimer's disease in Down syndrome.
Sun X; He G; Song W
FASEB J; 2006 Jul; 20(9):1369-76. PubMed ID: 16816112
[TBL] [Abstract][Full Text] [Related]
13. Characterization of monomeric and soluble aggregated Aβ in Down's syndrome and Alzheimer's disease brains.
Gkanatsiou E; Sahlin C; Portelius E; Johannesson M; Söderberg L; Fälting J; Basun H; Möller C; Odergren T; Zetterberg H; Blennow K; Lannfelt L; Brinkmalm G
Neurosci Lett; 2021 May; 754():135894. PubMed ID: 33848613
[TBL] [Abstract][Full Text] [Related]
14. App gene dosage modulates endosomal abnormalities of Alzheimer's disease in a segmental trisomy 16 mouse model of down syndrome.
Cataldo AM; Petanceska S; Peterhoff CM; Terio NB; Epstein CJ; Villar A; Carlson EJ; Staufenbiel M; Nixon RA
J Neurosci; 2003 Jul; 23(17):6788-92. PubMed ID: 12890772
[TBL] [Abstract][Full Text] [Related]
15. Targeting Amyloid-β Precursor Protein, APP, Splicing with Antisense Oligonucleotides Reduces Toxic Amyloid-β Production.
Chang JL; Hinrich AJ; Roman B; Norrbom M; Rigo F; Marr RA; Norstrom EM; Hastings ML
Mol Ther; 2018 Jun; 26(6):1539-1551. PubMed ID: 29628304
[TBL] [Abstract][Full Text] [Related]
16. Neprilysin Is Suppressed by Dual-Specificity Tyrosine-Phosphorylation Regulated Kinase 1A (DYRK1A) in Down-Syndrome-Derived Fibroblasts.
Kawakubo T; Mori R; Shirotani K; Iwata N; Asai M
Biol Pharm Bull; 2017; 40(3):327-333. PubMed ID: 28250274
[TBL] [Abstract][Full Text] [Related]
17. The effects of Cstb duplication on APP/amyloid-β pathology and cathepsin B activity in a mouse model.
Wu Y; Whittaker HT; Noy S; Cleverley K; Brault V; Herault Y; Fisher EMC; Wiseman FK
PLoS One; 2021; 16(7):e0242236. PubMed ID: 34292972
[TBL] [Abstract][Full Text] [Related]
18. USP25 inhibition ameliorates Alzheimer's pathology through the regulation of APP processing and Aβ generation.
Zheng Q; Song B; Li G; Cai F; Wu M; Zhao Y; Jiang L; Guo T; Shen M; Hou H; Zhou Y; Zhao Y; Di A; Zhang L; Zeng F; Zhang XF; Luo H; Zhang X; Zhang H; Zeng Z; Huang TY; Dong C; Qing H; Zhang Y; Zhang Q; Wang X; Wu Y; Xu H; Song W; Wang X
J Clin Invest; 2022 Mar; 132(5):. PubMed ID: 35229730
[TBL] [Abstract][Full Text] [Related]
19. Patient-specific Alzheimer-like pathology in trisomy 21 cerebral organoids reveals BACE2 as a gene dose-sensitive AD suppressor in human brain.
Alić I; Goh PA; Murray A; Portelius E; Gkanatsiou E; Gough G; Mok KY; Koschut D; Brunmeir R; Yeap YJ; O'Brien NL; Groet J; Shao X; Havlicek S; Dunn NR; Kvartsberg H; Brinkmalm G; Hithersay R; Startin C; Hamburg S; Phillips M; Pervushin K; Turmaine M; Wallon D; Rovelet-Lecrux A; Soininen H; Volpi E; Martin JE; Foo JN; Becker DL; Rostagno A; Ghiso J; Krsnik Ž; Šimić G; Kostović I; Mitrečić D; ; Francis PT; Blennow K; Strydom A; Hardy J; Zetterberg H; Nižetić D
Mol Psychiatry; 2021 Oct; 26(10):5766-5788. PubMed ID: 32647257
[TBL] [Abstract][Full Text] [Related]
20. Dual-specificity tyrosine(Y)-phosphorylation regulated kinase 1A-mediated phosphorylation of amyloid precursor protein: evidence for a functional link between Down syndrome and Alzheimer's disease.
Ryoo SR; Cho HJ; Lee HW; Jeong HK; Radnaabazar C; Kim YS; Kim MJ; Son MY; Seo H; Chung SH; Song WJ
J Neurochem; 2008 Mar; 104(5):1333-44. PubMed ID: 18005339
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
